Nuvation Bio stock
NUVBNYSENuvation Bio Inc., HealthcareISIN US67080N1019
29Score 29 out of 100, Weak
Price and trend
31 / 100
Price history
−18% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 36).
The price is 57% below its 52-week high. Largest decline in 6 years: 93% (March 2021 to October 2023).
Chart figures for advanced users
- SMA 50$5.19
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.33
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)36
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.05
- The lowest closing price of the last twelve months.
- Resistance$9.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Nuvation Bio Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.43B, is number 153 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $62.9M (up 699% year on year) and a loss of $204.63M.
- For fiscal 2026, analysts expect on average revenue of $194.5M (up 209.2%) and adjusted earnings per share of −$0.40.
Show more
- MEQIRI Score 29 out of 100 (Weak): rank 686 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $663.37M, financial debt $468.13M.
Weaknesses
- DilutionShare count up 57% since 2020.Capital allocation 18
- Loss-makingLoss of $135.93M over the last 12 months.Fundamentals 17
- High debtDebt 2.05 times equity (latest quarter), Biotechnology median 0.09.Stability 33
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 31 to 29.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 87%, operating −339%, net −325%. Last 12 months: net −67%. From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 108 days
- Last reported
- 4 Nov 2026EPS reported −$0.12 (expected −$0.12)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 10.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.40−0.7%
- Revenue
- $194.5M−0.5%
- Earnings per share
- −$0.21−10.9%
- Revenue
- $274.79M−2.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +3.6%No change in outlook; the launch is meeting expectations and spending patterns are not expected to change for the rest of the year.
“We do not expect changes to our general spending patterns for the remainder of the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $118,250 in total. 4 insiders sold, $2.13M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Nuvation Bio
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 29
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Immunocore HoldingsIMCR $1.57B45
- AbsciABSI $1.57B38
- Intellia TherapeuticsNTLA $1.48B33
- NovavaxNVAX $1.45B42
- AnaptysBioANAB $1.43B60
- Alto NeuroscienceANRO $1.42B41
- Ascentage Pharma Group InternationalAAPG $1.4B37
- Ocular TherapeutixOCUL $1.38B34
ETFs that hold Nuvation Bio
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.10% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.09% | 0.40% | €813.42M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.54B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.